Table 2. Changes in ANCA production over time.

in vitro ANCA unstim			n	mean	SD	median	IQR	p-value
	t = 0	no relapse	68	0.76	1.84	0.28	0.16–0.65	0.84
		relapse	15	1.07	2.47	0.28	0.18–0.52
	t = 1	no relapse	64	1.30	5.60	0.35	0.20–0.65	0.05
		relapse	13	16.84	54.47	0.70	0.26–4.71
	Δ0–1	no relapse	64	0.51	5.10	0.06	-0.06–0.20	0.10
		relapse	13	15.66	54.11	0.34	-0.02–1.97
in vitro ANCA stim
	t = 0	no relapse	68	12.26	34.22	0.94	0.26–6.61	0.19
		relapse	15	22.11	61.23	2.68	0.42–12.88
	t = 1	no relapse	64	16.17	35.98	1.59	0.43–12.28	0.43
		relapse	13	38.78	69.63	7.32	0.42–52.22
	Δ0–1	no relapse	64	3.40	21.35	0.20	-0.37–5.28	0.51
		relapse	13	14.94	59.72	2.18	-0.17–5.37
ANCA titer
	t = 0	no relapse	68	109.7	168.6	40	0–160	0.20
		relapse	15	146.7	204.9	80	40–160
	t = 1	no relapse	64	88.4	136.8	40	0–80	0.003
		relapse	13	192.3	178.8	80	80–320
	Δ0–1	no relapse	64	-14.4	84.1	0	-20–0	0.04
		relapse	13	32.3	147.8	20	0–100

ANCA, anti-neutrophil cytoplasmic antibody; IQR, interquartile range; PR3, proteinase 3; SD, standard deviation; stim, cell culture samples stimulated with CpG-oligodeoxynucleotides, B cell activating factor and interleukin-21; unstim, unstimulated cell culture samples.